Double Your Impact
By helping to fund life-changing research and world-class care, your gift creates more hope and possibility for every person with cancer. Your gift will be matched for Giving Tuesday.
Leading the fight against cancer. Always focused on you.
We deliver personalized treatment you won't get anywhere else, led by a team of world-renowned doctors, specialists, and scientists.
Changing how the world treats cancer through research
Our scientists pursue every aspect of cancer research — from exploring the fundamental biology of genes and cells, to developing immune-based treatments for cancer, uncovering the causes of metastasis, and more.
Let's get started
World-class experts. Close to you.
Many treatments and services are available at locations across NY and NJ.
Get care from the comfort of your home with telemedicine from MSK.
Explore MSK’s clinical trials
Our doctors and scientists work together so patients get access to cutting-edge treatments as soon as they are available.
Cancer news & discoveries
Article
FDA Approves Oral MEK Inhibitor Cobimetinib for Histiocytic Neoplasms, Research Led by Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) announced that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms (HN).
Read more
Podcast
Achieving Excellent Healthcare for All: A Candid Conversation with MSK’s New President & CEO, Dr. Selwyn Vickers
Dr. Selwyn Vickers was named President and CEO of Memorial Sloan Kettering Cancer Center in September 2022. His vision of a future with equal access and better outcomes for all has inspired the faculty and staff at MSK.
Listen now
Article
FDA Approves Teclistamab, a Promising New Drug for Multiple Myeloma Targeting BCMA and CD3 Proteins
Learn how FDA approval of a new multiple myeloma drug will brighten the outlook for people with resistant forms of the disease.
Read more